Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novo Nordisk’s oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic.
The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products.
Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies.
Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus.
Novo Nordisk, traded as CPSE:NOVO B, sits at a DKK282.95 share price, with the stock up 7.4% over the past week and 19.4% over the past month. These shorter term moves come alongside weaker longer term returns, including a 14.3% decline year to date and a 35.5% decline over the past year. This gives recent obesity pill momentum added significance for investors tracking a potential inflection in sentiment.
With oral semaglutide gaining attention and the FDA proposing tighter rules on compounded GLP-1 products, the competitive setup around branded obesity pills is shifting. Investors watching CPSE:NOVO B may focus on how long regulatory support and competitor delays persist, and how effectively Novo Nordisk converts this window into durable demand for its oral GLP-1 portfolio.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B Earnings & Revenue Growth as at May 2026
4 things going right for Novo Nordisk that this headline doesn’t cover.
Quick Assessment
✅ Price vs Analyst Target: At DKK282.95, the stock sits around 8% below the DKK307.67 analyst price target.
✅ Simply Wall St Valuation: Shares are flagged as trading 62.9% below the platform’s estimated fair value.
✅ Recent Momentum: The 30 day return of 19.4% shows strong short term price strength.
There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value.
Key Considerations
📊 Oral semaglutide gaining obesity market momentum, combined with the FDA compounding proposal and Lilly’s pill delay, strengthens the current GLP 1 pill position.
📊 Watch how prescription volumes, pricing changes and any updates on regulatory timelines track against the recent 19.4% 30 day return.
⚠️ The company faces 5 flagged risks including high debt levels, an uncovered dividend by free cash flow and a high level of non cash earnings.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can check out the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com